AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24447510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection into the ALT
Number of subjects: 16
Study 24447510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injections
Number of subjects: 16
Study 23225029 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized assessment incorporating the Clinician Administered PTSD Scale and the World Health Organization Disability Assessment Schedule‐II
Number of subjects: 384
Study 23225029 — intervention group
Group type: COMPARATOR
Intervention: Usual disability examiner practices for PTSD
Number of subjects: 384
Study 19737594 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMA/water primer
Number of subjects: 5
Study 19737594 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMA/acetone primer
Number of subjects: 5
Study 19737594 — intervention group
Group type: EXPERIMENTAL
Intervention: Free surface evaporation
Number of subjects: 5
Study 19737594 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentine cubes evaporation
Number of subjects: 5
Study 18198311 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump rope exercise training (40 min/d, 5 d/wk for 6 weeks)
Number of subjects: 26
Study 18198311 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 26
Study 15105105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir at 800/200 mg BID (arm 1)
Number of subjects: 32
Study 15105105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir at 400/400 mg BID (arm 2)
Number of subjects: 32
Study 15105105 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin at 600 mg once daily
Number of subjects: 32
Study 15105105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir combined with rifampin
Number of subjects: 32
Study 10955700 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 200 microg daily
Number of subjects: 122
Study 10955700 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 100 microg daily
Number of subjects: 122
Study 10955700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 10955700 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (100 or 200 microg daily)
Number of subjects: 122
Study 10955700 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 122
Study 9101424 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day of an 85% concentrate of the ethyl esters of eicosapentenoic and docosahexaenoic acids for 6 weeks
Number of subjects: 40
Study 9101424 — intervention group
Group type: COMPARATOR
Intervention: 4 g/day of ethyl esters of corn oil fatty acids
Number of subjects: 40
Study 9101424 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day of an 85% concentrate of the ethyl esters of eicosapentenoic and docosahexaenoic acids
Number of subjects: 40
Study 8267193 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg
Number of subjects: 72
Study 8267193 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg
Number of subjects: 72
Study 8267193 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 1 mg
Number of subjects: 72
Study 8267193 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 3 mg
Number of subjects: 72
Study 8267193 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg and 3 mg)
Number of subjects: 72
Study 8267193 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 72
Study 2860156 — intervention group
Group type: EXPERIMENTAL
Intervention: Local, intra-operative administration of povidone-iodine
Number of subjects: 250
Study 2860156 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic antibiotic therapy
Number of subjects: 250
Study 3113246 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol, 800 micrograms to 1,200 micrograms daily in four to six divided doses, for periods of from one day to 17 months.
Number of subjects: 157
Study 31190495 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with penetrating moxibustion
Number of subjects: 60
Study 31190495 — intervention group
Group type: COMPARATOR
Intervention: Biological feedback training of pelvic floor muscle
Number of subjects: 60
Study 31190495 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EA + moxibustion and control)
Number of subjects: 60
Study 27750353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes screening and treatment program in Ward-A
Number of subjects: 0
Study 27750353 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment in Ward-B
Number of subjects: 0
Study 27750353 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients requiring percutaneous coronary intervention (PCI) in Ward-A
Number of subjects: 0
Study 27750353 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without PCI in Ward-A
Number of subjects: 0
Study 26173842 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based brief intervention (IBI) consisting of normative feedback, feedback on consequences of alcohol use, calorific value of reported consumption, computed blood alcohol concentration for reported consumption, indication of risk, information on alcohol and health, recommendations indicating low-risk drinking limits.
Number of subjects: 737
Study 26173842 — intervention group
Group type: COMPARATOR
Intervention: Control condition: no intervention (assessment only).
Number of subjects: 737
Study 22911373 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES + ERGO training
Number of subjects: 14
Study 22911373 — intervention group
Group type: COMPARATOR
Intervention: Control + ERGO training
Number of subjects: 14
Study 21998703 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir
Number of subjects: 4758
Study 21998703 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine-tenofovir
Number of subjects: 4758
Study 21998703 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 4758
Study 17681994 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational health service consultation for high risk group (n = 209)
Number of subjects: 1341
Study 17681994 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone advice centre for intermediate risk group (n = 268)
Number of subjects: 1341
Study 16435115 — intervention group
Group type: EXPERIMENTAL
Intervention: (11)C‐methionine PET/CT
Number of subjects: 18
Study 16435115 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal parathyroidectomy
Number of subjects: 18
Study 15050085 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined psychotherapy and pharmacotherapy for depression
Number of subjects: 53
Study 15050085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 53
Study 15050085 — intervention group
Group type: EXPERIMENTAL
Intervention: Double depression (major depression plus dysthymia)
Number of subjects: 53
Study 15050085 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of heroin use
Number of subjects: 53
Study 10652955 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (APD) 30 mg i.v. in 500 ml D5W over 4 hours
Number of subjects: 0
Study 10652955 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (APD)
Number of subjects: 0
Study 10652955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9284985 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with extracts of Dermatophagoides pteronyssinus (Dpt) or D. farinae (Dfa) (Alutard SQ, ALK, Denmark)
Number of subjects: 31
Study 9284985 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 31
Study 8367775 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reinfusion of autologous blood
Number of subjects: 57
Study 8367775 — intervention group
Group type: COMPARATOR
Intervention: Delayed reinfusion of autologous blood
Number of subjects: 57
Study 8367775 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reinfusion in A/P and PSF groups
Number of subjects: 57
Study 8367775 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and delayed reinfusion groups
Number of subjects: 57
Study 2875053 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 33
Study 2875053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 30099405 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention (CTI)
Number of subjects: 0
Study 30099405 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 0
Study 30099405 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Number of subjects: 0
Study 30099405 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 27074137 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-screen, high-definition (WSHD) monitors
Number of subjects: 152
Study 27074137 — intervention group
Group type: COMPARATOR
Intervention: Standard monitors (SD)
Number of subjects: 152
Study 24521021 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus
Number of subjects: 88
Study 24521021 — intervention group
Group type: COMPARATOR
Intervention: calcineurin inhibitor
Number of subjects: 88
Study 23750536 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate supplement + carbohydrate drink (GLU+CHO)
Number of subjects: 9
Study 23750536 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate supplement + placebo drink (GLU)
Number of subjects: 9
Study 23750536 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement + carbohydrate drink (CHO)
Number of subjects: 9
Study 23750536 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement + placebo drink (CON)
Number of subjects: 9
Study 20510247 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced 6% HES 130/0.4 plus a balanced crystalloid (n = 30)
Number of subjects: 60
Study 20510247 — intervention group
Group type: COMPARATOR
Intervention: Unbalanced HES-in-saline plus saline (n = 30)
Number of subjects: 60
Study 18609122 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg ranitidine as a bolus intravenously
Number of subjects: 12
Study 18609122 — intervention group
Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 12
Study 16382112 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin (TP)
Number of subjects: 680
Study 16382112 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and cisplatin (CP)
Number of subjects: 680
Study 14697932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap Arpimune ME (test formulation)
Number of subjects: 30
Study 14697932 — intervention group
Group type: COMPARATOR
Intervention: Cap Sandimmune Neoral (reference formulation)
Number of subjects: 30
Study 10910856 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 degrees tilt-up position (TUP)
Number of subjects: 20
Study 10910856 — intervention group
Group type: COMPARATOR
Intervention: horizontal posture
Number of subjects: 20
Study 8738312 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 1200
Study 8738312 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprotiline
Number of subjects: 1200
Study 8738312 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1200
Study 8738312 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 1200
Study 8738312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 8738312 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments
Number of subjects: 1200
Study 8738312 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 1200
Study 1348396 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% apraclonidine HCl
Number of subjects: 329
Study 1348396 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 329
Study 3924617 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin system (TNS) 20 cm2 or greater
Number of subjects: 56
Study 3924617 — intervention group
Group type: COMPARATOR
Intervention: Transdermal nitroglycerin system (TNS) 10 cm2
Number of subjects: 56
Study 30908082 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg BI 653048
Number of subjects: 3
Study 30908082 — intervention group
Group type: COMPARATOR
Intervention: 20 mg prednisolone
Number of subjects: 3
Study 29954713 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weekly stage-tailored messages on healthful behaviors for 10 weeks; and 3 monthly stage-tailored messages and 1 monthly e-mail encouraging a visit to the portal page after the 3-month physical assessment
Number of subjects: 156
Study 29954713 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 156
Study 26784939 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol 50 mg tablet (oral administration)
Number of subjects: 40
Study 26016363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligustrazine treatment (80 mg/d; i.v.; for 2 weeks) in addition to standard treatment
Number of subjects: 70
Study 26016363 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with antibiotics, antiasthmatic and expectorant medications, and oxygenation
Number of subjects: 70
Study 21862953 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with intravitreal ranibizumab and topical bromfenac
Number of subjects: 30
Study 21862953 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab alone
Number of subjects: 30
Study 19668346 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (MHT)
Number of subjects: 0
Study 19668346 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17599879 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 144
Study 15177709 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects who had recently fallen in love
Number of subjects: 24
Study 15177709 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects who had recently fallen in love (men)
Number of subjects: 24
Study 15177709 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects who had recently fallen in love (women)
Number of subjects: 24
Study 15177709 — intervention group
Group type: COMPARATOR
Intervention: Subjects who were single or in a long-lasting relationship
Number of subjects: 24
Study 15177709 — intervention group
Group type: COMPARATOR
Intervention: Subjects who were single or in a long-lasting relationship (men)
Number of subjects: 24
Study 15177709 — intervention group
Group type: COMPARATOR
Intervention: Subjects who were single or in a long-lasting relationship (women)
Number of subjects: 24
Study 11125353 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (InterStim system)
Number of subjects: 177
Study 11125353 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed implantation for 6 months)
Number of subjects: 177
Study 11125353 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary inactivation of sacral nerve stimulation therapy
Number of subjects: 177
Study 9743652 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Treatment (TPs and scanner technique)
Number of subjects: 324
Study 9743652 — intervention group
Group type: COMPARATOR
Intervention: Trigger points technique
Number of subjects: 324
Study 9743652 — intervention group
Group type: COMPARATOR
Intervention: Scanner technique
Number of subjects: 324
Study 8170098 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar anesthesia (PERI) with 6, 8 or 10 ml of bupivacaine-lidocaine-hyaluronidase mixture
Number of subjects: 160
Study 8170098 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia (RETRO) using Unsold technique with 5 ml of bupivacaine-lidocaine-hyaluronidase mixture and Nadbath/Rehman facial nerve block (5 ml etidocaine-lidocaine mixture)
Number of subjects: 160
Study 8170098 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods of anesthesia (including both PERI and RETRO)
Number of subjects: 160
Study 8170098 — intervention group
Group type: EXPERIMENTAL
Intervention: RETRO and PERI
Number of subjects: 160
Study 2972897 — intervention group
Group type: EXPERIMENTAL
Intervention: oestradiol valerate/cyproterone acetate (Group A)
Number of subjects: 50
Study 2972897 — intervention group
Group type: COMPARATOR
Intervention: oestradiol valerate/norethisterone (Group B)
Number of subjects: 50
Study 29521683 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI of at least 35 kg/m
Number of subjects: 11886
Study 29521683 — intervention group
Group type: COMPARATOR
Intervention: BMI categories (overall, nonaggressive, aggressive prostate cancer including all Gleason 7 cases)
Number of subjects: 11886
Study 28929560 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (10 mg/kg intravenous)
Number of subjects: 20
Study 28929560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26518774 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First plus Assertive Community Treatment
Number of subjects: 497
Study 26518774 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing first plus intensive case management
Number of subjects: 497
Study 26518774 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 497
Study 25136552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tradamix TX1000 (alga Ecklonia bicyclis, Tribulus terrestris, glucosamine oligosaccharide)
Number of subjects: 177
Study 25136552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tradamix TX1000
Number of subjects: 177
Study 25136552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 22235821 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (60 mg)
Number of subjects: 23
Study 22235821 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg)
Number of subjects: 23
Study 22235821 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of furosemide and hydrochlorothiazide
Number of subjects: 23
Study 20178212 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil‐SE (self‐etch, water‐based) at 5.0 cm water pressure
Number of subjects: 24
Study 20178212 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil‐SE (self‐etch, water‐based) at 15.0 cm water pressure
Number of subjects: 24
Study 20178212 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step Plus (total‐etch, acetone‐based) at 5.0 cm water pressure
Number of subjects: 24
Study 20178212 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step Plus (total‐etch, acetone‐based) at 15.0 cm water pressure
Number of subjects: 24
Study 20178212 — intervention group
Group type: EXPERIMENTAL
Intervention: PQ1 (total‐etch, ethanol‐based) at 0.0, 5.0, and 15.0 cm water pressure
Number of subjects: 24
Study 20178212 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak‐SE (self‐etch, ethanol‐based) at 0.0, 5.0, and 15.0 cm water pressure
Number of subjects: 24
Study 20178212 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil‐SE (self‐etch, water‐based) at 0.0 cm water pressure
Number of subjects: 24
Study 20178212 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step Plus (total‐etch, acetone‐based) at 0.0 cm water pressure
Number of subjects: 24
Study 20178212 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak‐SE (self‐etch, ethanol‐based) at 0.0 cm water pressure
Number of subjects: 24
Study 20178212 — intervention group
Group type: EXPERIMENTAL
Intervention: PQ1 (total‐etch, ethanol‐based) at 0.0 cm water pressure
Number of subjects: 24
Study 20178212 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak‐SE (self‐etch, ethanol‐based) at 5.0 cm water pressure
Number of subjects: 24
Study 20178212 — intervention group
Group type: EXPERIMENTAL
Intervention: PQ1 (total‐etch, ethanol‐based) at 5.0 cm water pressure
Number of subjects: 24
Study 17131317 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori seropositivity
Number of subjects: 1143
Study 17131317 — intervention group
Group type: EXPERIMENTAL
Intervention: antiCagA antibodies
Number of subjects: 1143
Study 17131317 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe chronic atrophic gastritis (SCAG) defined as PGA <22 microg/l
Number of subjects: 1143
Study 17131317 — intervention group
Group type: EXPERIMENTAL
Intervention: CagA seropositivity
Number of subjects: 1143
Study 17131317 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe chronic atrophic gastritis (SCAG)
Number of subjects: 1143
Study 15878384 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic warfarin sodium product
Number of subjects: 35
Study 15878384 — intervention group
Group type: COMPARATOR
Intervention: Branded warfarin sodium product
Number of subjects: 35
Study 12186116 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (Insulin only, 50 patients)
Number of subjects: 188
Study 12186116 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (Insulin + GBC 20 mg/day, 49 patients)
Number of subjects: 188
Study 12186116 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (Morning insulin + GBC 20 mg/day, 43 patients)
Number of subjects: 188
Study 12186116 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (Evening insulin + GBC 20 mg/day, 46 patients)
Number of subjects: 188
Study 9875835 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 0
Study 9875835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9382910 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDCAP
Number of subjects: 35
Study 9382910 — intervention group
Group type: COMPARATOR
Intervention: Routine infant care (Control)
Number of subjects: 35
Study 1773076 — intervention group
Group type: EXPERIMENTAL
Intervention: Air caloric irrigation at 8 L/min for 45 seconds
Number of subjects: 30
Study 1773076 — intervention group
Group type: EXPERIMENTAL
Intervention: Air caloric irrigation at 8 L/min for 60 seconds
Number of subjects: 30
Study 1773076 — intervention group
Group type: EXPERIMENTAL
Intervention: Air caloric irrigation at 8 L/min for 75 seconds
Number of subjects: 30
Study 1773076 — intervention group
Group type: EXPERIMENTAL
Intervention: Air caloric irrigation at 8 L/min for 10-beat and 10-sec measurements
Number of subjects: 30
Study 1773076 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard error of measurement for SPV calculations
Number of subjects: 30